Nice

News

NICE aims to improve communications with UK life sciences

NICE has announced a collaboration with an organisation representing UK life sciences, to improve communications between the cost-effectiveness body and industry.

Views & Analysis

Market access roundup: The US fights back against price hike...

Don’t expect the US government’s war on drug pricing to go away any time soon – for once president Trump and his rivals, the Democrat party, agree on something, and both have had some stron

News

NICE assessments could reform in new superbug plan

The UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a new NHS reimbursement scheme backed by NICE to encourage pharma to develop

News

Vertex’s CF drug gets label extension as pricing row continu...

While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in you

News

Scotland's NHS could reimburse Vertex CF drugs, price row on...

Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.

News

NICE rejects Alnylam and Akcea's amyloidosis drugs

NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance.

NICE aims to improve communications with UK life sciences

Market access roundup: The US fights back against price hike...

NICE assessments could reform in new superbug plan

Vertex’s CF drug gets label extension as pricing row continu...

Scotland's NHS could reimburse Vertex CF drugs, price row on...

NICE rejects Alnylam and Akcea's amyloidosis drugs

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Nice

Editor's Picks